<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31725">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01838018</url>
  </required_header>
  <id_info>
    <org_study_id>8777</org_study_id>
    <nct_id>NCT01838018</nct_id>
  </id_info>
  <brief_title>Brain Perfusion in Pantothenate Kinase-associated Neurodegeneration (PKAN)</brief_title>
  <official_title>Brain Perfusion in Pantothenate Kinase-Associated Neurodegeneration (PKAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Susan J. Hayflick</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Clinical and Translational Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn whether blood flow in the brain is normal in people
      with pantothenate kinase-associated neurodegeneration (PKAN).  Specifically, preliminary
      data suggest a region of the brain called the globus pallidus (GP), a key region affected by
      PKAN, may have reduced blood flow. Standard MRI and perfusion scanning techniques will be
      used to learn about cerebral blood flow in the globus pallidus and compare it to blood flow
      in other brain regions as well as to healthy controls.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>ASL-derived cerebral blood flow(CBF)</measure>
    <time_frame>Single MRI</time_frame>
    <safety_issue>No</safety_issue>
    <description>The unit of analyses will be the subject and the primary comparison will be the globus pallidus CBF between PKAN and healthy controls.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Pantothenate Kinase-associated Neurodegeneration (PKAN)</condition>
  <arm_group>
    <arm_group_label>PKAN</arm_group_label>
    <description>This group consists of individuals diagnosed with PKAN using a combination of MRI and PANK2 gene sequencing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>This is a control group of healthy volunteers, matched with the PKAN group for age and sex.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The PKAN group consists of individuals in the United States diagnosed with PKAN.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of PKAN confirmed by MRI and gene testing

          -  able to undergo MRI for approximately 1 hour without sedation

        Exclusion Criteria:

          -  deep brain stimulators or other conditions that warrant avoidance of a strong
             magnetic field

          -  previous reaction to gadolinium (Gd) contrast agent

          -  acute or chronic kidney dysfunction

          -  pregnant and/or nursing at time of study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan J Hayflick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allison M Gregory, MS</last_name>
    <phone>503-494-4344</phone>
    <email>gregorya@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison M Gregory, MS</last_name>
      <phone>503-494-4344</phone>
      <email>gregorya@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Susan J Hayflick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ohsu.edu/xd/education/schools/school-of-medicine/departments/basic-science-departments/molecular-and-medical-genetics/people/primary-faculty/susan-hayflick.cfm</url>
  </link>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 22, 2013</lastchanged_date>
  <firstreceived_date>April 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health &amp; Science University</investigator_affiliation>
    <investigator_full_name>Susan J. Hayflick</investigator_full_name>
    <investigator_title>Professor &amp; Chair, Molecular &amp; Medical Genetics</investigator_title>
  </responsible_party>
  <keyword>PKAN</keyword>
  <keyword>brain iron</keyword>
  <keyword>NBIA</keyword>
  <keyword>neurodegeneration with brain iron accumulation</keyword>
  <keyword>Hallervorden Spatz Syndrome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pantothenate Kinase-Associated Neurodegeneration</mesh_term>
    <mesh_term>Nerve Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
